Laparoscopic adrenalectomy vs. radiofrequency ablation for the treatment of primary aldosteronism. A single center retrospective cohort analysis adjusted with propensity score

2021 ◽  
Author(s):  
Oscar Cano-Valderrama ◽  
Jimena González-Nieto ◽  
María Abad-Cardiel ◽  
Santiago Ochagavía ◽  
Isabelle Rünkle ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Propensity Score ◽  
Primary Aldosteronism ◽  
Laparoscopic Adrenalectomy ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Single Center ◽  
Retrospective Cohort Analysis

scholarly journals Predictors of blood loss in lung transplant surgery—a single center retrospective cohort analysis

2019 ◽  
Vol 11 (11) ◽  
pp. 4755-4761 ◽  
Author(s):  
Bastian Grande ◽  
Pascal Oechslin ◽  
Martin Schlaepfer ◽  
Burkhardt Seifert ◽  
Ilhan Inci ◽  
...  
Keyword(s):  
Blood Loss ◽  
Retrospective Cohort ◽  
Lung Transplant ◽  
Cohort Analysis ◽  
Single Center ◽  
Retrospective Cohort Analysis

Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3658-3658
Author(s):  
Anthony R Mato ◽  
Ewelina A Protomastro ◽  
Tania Zielonka ◽  
Tatyana Feldman ◽  
Scott D Rowley ◽  
...  
Keyword(s):  
Board Of Directors ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
High Dose ◽  
Single Center ◽  
Front Line ◽  
Advisory Committees ◽  
Retrospective Cohort Analysis ◽  
Lr Test ◽  
Line Setting

Abstract Abstract 3658 Background: While current front-line treatment options for the management of MCL are still debated, a growing consensus in the lymphoma community suggest that MCL pts show superior outcomes with either consolidative ASCT or dose-intensive treatment approaches over CHOP-like regimens and that cytarabine containing regimens achieve earlier and deeper (hence more durable) responses. On the other hand, such dose-intensive strategies can be difficult to administer to the elderly (a relevant issue with a median age at diagnosis of mid 60's) or in pts with comorbidities. Few studies have looked at the comparative effectiveness of initial therapies in MCL in the community setting. Methods: Utilizing KM and Cox regression analyses, we performed a single-center, retrospective cohort analysis to describe the survival experience of 139 MCL pts (med follow up 50 months) treated in the front-line setting with R-CHOP (n=35), R-HCVAD (n=63) or induction-chemotherapy followed by HDT-ASCT (n=41). The primary endpoints of this retrospective cohort analysis were overall (OS) and progression free survival (PFS). The proportional hazards assumption was met for this analysis. Results: The JTCC MCL outcomes database contains 214 total patient entries (newly dx + relapsed MCL) from 1993–2012 of which 139 pts met inclusion/exclusion criteria with complete outcomes data available. The R-CHOP, R-HCVAD and HDT-ASCT groups were comparable in terms of known prognostic factors including age (median 60), ECOG PS (median 1), MIPI score (median score 4, 30% int risk, 29% high risk) and Ki-67 (median 30% and range 5–95%). The median PFS was superior for pts treated with either R-HCVAD (53 months) or ASCT (63 months) (p=<.001, LR test, Figure) compared to R-CHOP (24 months). No significant difference (HR 1.15, p=.7, 95%CI .5–2.5) in PFS could be detected between pts age < 65 vs. those age >= 65 (n=25) treated with either R-HCVAD (med PFS 46 months) or HDT-ASCT (med PFS 54 months). Median OS favored pts treated with R-HCVAD or HDT-ASCT (103 months and 108 months respectively) over R-CHOP (67 months) but did not meet statistical significance (p=.16, LR test). Conclusions: These data represent the largest published single center experience of MCL patients treated in the front-line setting. Our results confirm a recent NCCN report showing benefit of dose-intensive/high dose strategies in MCL over conventional therapy with more than doubling median PFS over R-CHOP. Of notice when compared to recently updated STiL trial (Rummel ASCO 2012, abst #3) our results are c/w with a median PFS of 22 months after R-CHOP but appear superior to med PFS (35 months) seen with bendamustine-rituximab in MCL even in a subset of elderly pts >= age 65. Our results support the use of dose-intensive strategies in a fit geriatric patient population. Finally the excellent PFS seen in that setting represents a promising platform for integrating novel agents in combination and/or maintenance in future strategies to prevent recurrence and continue to improve MLC pts outcome. Disclosures: Mato: Genentech: Speakers Bureau; Seattle Genetics: Speakers Bureau; Millennium: Speakers Bureau; Celgene: Speakers Bureau. Feldman:Allos: Speakers Bureau; celgene: Speakers Bureau; Seattle Genetics: Speakers Bureau; Merck: Speakers Bureau. Goy:Milennium: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; J & J: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees.

scholarly journals Apnea Test Safety in Brain Death: A Single-Center Retrospective Cohort Analysis

2021 ◽  
Vol 11 (1-2) ◽  
pp. 14-19
Author(s):  
Talita Sansoni ◽  
Nicholas Nascimento ◽  
Gabriel Franco ◽  
Rui Moreno ◽  
Alexandre Barros ◽  
...  
Keyword(s):  
Brain Death ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Single Center ◽  
Apnea Test ◽  
Retrospective Cohort Analysis

A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma

2020 ◽  
Vol 61 (5) ◽  
pp. 1211-1219 ◽  
Author(s):  
Swetha Kambhampati ◽  
Derek Galligan ◽  
Chiung-Yu Huang ◽  
Sandy Wong ◽  
Jeffrey Wolf ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Single Center ◽  
Refractory Multiple Myeloma ◽  
Retrospective Cohort Analysis

Retrospective cohort analysis of 926 tricuspid valve surgeries: Clinical and hemodynamic outcomes with propensity score analysis

2012 ◽  
Vol 163 (5) ◽  
pp. 851-858.e1 ◽  
Author(s):  
Guillaume Marquis-Gravel ◽  
Denis Bouchard ◽  
Louis P. Perrault ◽  
Pierre Pagé ◽  
Hugues Jeanmart ◽  
...  
Keyword(s):  
Propensity Score ◽  
Tricuspid Valve ◽  
Retrospective Cohort ◽  
Propensity Score Analysis ◽  
Cohort Analysis ◽  
Retrospective Cohort Analysis ◽  
Score Analysis

scholarly journals Impact of Liver Injury in COVID-19 Patients: Single-center Retrospective Cohort Analysis

2020 ◽  
Vol 8 (4) ◽  
pp. 1-3
Author(s):  
Jiten Desai ◽  
Upenkumar Patel ◽  
Shiva Arjun ◽  
Kristen Farraj ◽  
Kevin Yeroushalmi ◽  
...  
Keyword(s):  
Liver Injury ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Single Center ◽  
Retrospective Cohort Analysis

scholarly journals Case Report and Cohort Analysis of Drug-Induced Liver Injury Associated with Daptomycin

2014 ◽  
Vol 58 (8) ◽  
pp. 4902-4903 ◽  
Author(s):  
Nicole Bohm ◽  
Charles Makowski ◽  
Mario Machado ◽  
Adam Davie ◽  
Nelson Seabrook ◽  
...  
Keyword(s):  
Case Report ◽  
Liver Injury ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Single Center ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Retrospective Cohort Analysis ◽  
Creatinine Kinase Level

ABSTRACTA patient receiving daptomycin developed asymptomatic transaminitis and hyperbilirubinemia without concurrent multiorgan dysfunction or elevation of his creatinine kinase level. After ruling out other etiologies, the liver injury was attributed to daptomycin and was subsequently resolved. A single-center retrospective cohort analysis of baseline and follow-up liver function panels (n= 614) from all admissions from 2008 to 2013 during which daptomycin was administered did not reveal any other cases of probable or definite drug-induced liver injury associated with daptomycin.

Sign in / Sign up

Export Citation Format

Share Document